Multinational healthcare company Johnson & Johnson (NYSE:JNJ) in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Johnson & Johnson (JNJ) stock saw a modest uptick, ending the day at $152.89 which represents a slight increase of $6.07 or 4.13% from the prior close of $146.82. The stock opened at $ and touched a ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other healthcare stocks. Healthcare stocks are widely considered a cornerstone of a retirement ...

We recently published a list of Jim Cramer is Talking About These 10 Stocks. In this article, we are going to take a look at ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...